Drug evaluation: Tagatose in the treatment of type 2 diabetes and obesity
- ISBN: 1472-4472
Spherix Inc (formerly Biospherics) is developing tagatose, an orally active lactose derivative for the potential treatment of obesity and type 2 diabetes. The compound is also under investigation for the potential treatment of anemia, hemophilia and medical problems related to infertility, birth weight and excessive maternal food intake. Phase I and II clinical trials have been completed. (copyright) The Thomson Corporation.